DAS
IBRX icon

Daybright Advisory Services’s ImmunityBio IBRX Stock Holding History

Daybright Advisory Services’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Hold
14,819
– – 0.03% 145
2026
Q1 		$114K Hold
14,819
– – 0.03% 133
2025
Q4 		$29.3K Buy
+14,819
New +$33.6K 0.01% 133

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Daybright Advisory Services's IBRX Position: Q2 2026 in Review

Daybright Advisory Services held its ImmunityBio (IBRX) position steady in Q2 2026 at 14,819 shares worth $106K. The position accounts for 0.03% of the portfolio, ranked #145.

Daybright Advisory Services first reported a position in IBRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $114K in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Daybright Advisory Services held 14,819 shares of ImmunityBio worth $106K as of Q2 2026.
  • Daybright Advisory Services left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up 0.03% of Daybright Advisory Services's portfolio in Q2 2026, its #145 holding.
  • Daybright Advisory Services first reported a position in ImmunityBio in Q4 2025 and has held it in 3 quarters since.
  • Daybright Advisory Services's ImmunityBio position peaked at $114K in Q1 2026.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Daybright Advisory Services's 13F filing for Q2 2026, filed 4 Aug 2026.